MORE►
VT-X7
Osteal Therapeutics, a clinical-stage biopharmaceutical company, says it's developing "a new category" of combination therapies for orthopedic infections. The new funding round, led by Asteroid Partners, will help Osteal accelerate preparation for commercial launch of VT-X7, its lead therapy for the treatment of periprosthetic joint infection, the company said.
Dallas BioPharma Closes $23M Series C Funding
by Lance Murray | Sep 21, 2023
Osteal Therapeutics, a clinical-stage biopharmaceutical company, says it's developing "a new category" of combination therapies for orthopedic infections. The new funding round, led by Asteroid Partners, will help Osteal accelerate preparation for commercial launch of VT-X7, its lead therapy for the treatment of periprosthetic joint infection, the company said.
